Skip to main content
Premium Trial:

Request an Annual Quote

Definiens Raises $20.4M in Private Financing Round

NEW YORK (GenomeWeb) – Definiens announced today that it has raised €15 million ($20.4 million) in a private round of financing that will support the firm's efforts to expand its business into digital tissue diagnostics.

The Munich, Germany-based digital pathology products firm said the funds will help it advance its tissue phenomics strategy, which is based on its Cognition Network technology, a big data approach to developing tissue-based diagnostics for oncology and immunotherapy. Definiens believes its strategy will enable better prediction of patient outcomes and identification of drug responders.

The financing round was led by Wellington Partners with participation from Glide Healthcare and existing investors Cipio Partners and TVM Capital. In conjunction with the financing, Wellington General Partner and Managing Director Rainer Strohmenger will join Definiens' board of directors.

"We believe that Definiens now is approaching an inflection point which will have a significant impact on the growth potential and strategic value of this business for the leading players in imaging, diagnostics, and oncology drug development," Strohmenger said in a statement.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.